Does smoking impact dopamine neuronal loss in de novo Parkinson disease?
Yoonju LeeJungsu S OhSeok Jong ChungSu Jin ChungSoo-Jong KimChung Mo NamPhil Hyu LeeJae Seung KimYoung H SohnPublished in: Annals of neurology (2017)
This study analyzed data from dopamine transporter (DAT) positron emission tomographic scans of 282 male patients with de novo Parkinson disease to investigate whether smoking impacts striatal dopamine neuronal degeneration. Mean DAT activity in the posterior (p = 0.016) and ventral putamen (p = 0.028) was higher in 44 current smokers in comparison to 105 ex-smokers and 133 never-smokers. The severity of baseline motor deficits and the longitudinal increases in levodopa-equivalent doses during follow-up were similar among the 3 groups. These results suggest that current smoking, but not past smoking, protects dopamine neuronal degeneration in the sensorimotor striatum with no additional clinical benefits. Ann Neurol 2017;82:850-854.